Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.37 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | GLP1R | P43220 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12124198 | 0.76 | DYRK1A (0.46) | NR2F2HCAR2P2RX7IKBKBKDM4E | |
| SCHEMBL10384446 | 0.76 | NOTUM (0.31) | P2RX7 | |
| SCHEMBL3464161 | 0.76 | HCAR2 (0.44) | HCAR2DYRK1A | |
| SCHEMBL2876840 | 0.74 | ALOX15 (0.35) | — | |
| SCHEMBL13163267 | 0.74 | NOTUM (0.30) | P2RX7 | |
| SCHEMBL13162514 | 0.74 | HCAR2 (0.42) | NR2F2HCAR2P2RX7IKBKBKDM4E | |
| SCHEMBL2876838 | 0.74 | — | — | |
| SCHEMBL13184189 | 0.74 | GLP1R (0.39) | P2RX7GLP1R | |
| SCHEMBL13162566 | 0.73 | IKBKB (0.41) | NR2F2IKBKBKDM4EPOLBMAPT | |
| SCHEMBL3664303 | 0.73 | NR2F2 (0.32) | NR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | claimed |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2023-03-07 | — | — | US | claimed |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | disclosed |
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2023-03-07 | — | — | US | disclosed |
| EP-3253210-B1 | 2-(HET) ARYL-SUBSTITUTED CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2021-11-24 | — | — | EP | disclosed |
| US-20210093613-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-20210093613-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-20070093467-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093467-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| WO-2007044885-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007027734-A2 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | CHEMOCENTRYX, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093613-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | NR2F2 752/4885HCAR2 153/4885P2RX7 2306/4885 |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC1 | NR2F2 3710/4885HCAR2 3796/4885P2RX7 145/4885 |
| US-20070093467-A1 | Piperidine derivatives and methods of use | CCR1, CCR3, CCR4 | NR2F2 1209/4885HCAR2 23/4885P2RX7 139/4885 |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC1 | NR2F2 3710/4885HCAR2 3796/4885P2RX7 145/4885 |
| US-11759454-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | NR2F2 752/4885HCAR2 153/4885P2RX7 2306/4885 |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC3 | NR2F2 3689/4885HCAR2 3821/4885P2RX7 139/4885 |
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CXCR2 | NR2F2 903/4885HCAR2 106/4885P2RX7 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.